Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.


Although the first studies using DNA demethylating agents at low doses in hematologic neoplasia and hemoglobinopathies were initiated more than 20 years ago, development of this type of nonintensive treatment has only been spurred in the last 6 to 8 years by the discovery of many genes that are specifically hypermethylated in cancer. These provide a… (More)


  • Presentations referencing similar topics